17th December 2012, London: – Advent Life Sciences announced today the appointment of Ian Nicholson as an Operating Partner. Ian brings over 20 years of international experience in management, licensing, mergers and acquisitions in the life sciences sector. He was most recently CEO of Chroma Therapeutics Ltd, prior to which he held senior positions at Celltech Group plc, Oxford Asymmetry, Lonza AG and Amersham International plc. Ian has served on the Boards of several Public and Private Companies in the UK and Europe. Ian holds a BSc (Hons) from University College London and an MBA from Boston University.
– Ends –
About Advent Life Sciences:
Advent Life Sciences is the dedicated Life Sciences team at Advent Venture Partners, one of Europe’s best established growth and venture capital firms. Advent Life Sciences invests predominantly in early-stage and growth equity life sciences companies in the UK, Europe and the US. It will back companies that have a first- or best-in-class approach in a range of sectors within the life sciences sector, including new drug discovery, enabling technologies, med-tech and diagnostics.
Advent Life Sciences is a leader in European life sciences venture capital. Its investments include: PowderMed, a therapeutic DNA vaccine company sold to Pfizer; Thiakis, an obesity treatment company acquired by Wyeth Pharmaceuticals; Respivert, a drug discovery company focused on respiratory diseases that was acquired by Johnson & Johnson; EUSA Pharma, a transatlantic speciality pharmaceutical company acquired by Jazz Pharmaceuticals; Avila Therapeutics, a biotechnology company developing targeted covalent drugs acquired by Celgene Corporation, Micromet, a biotechnology company acquired by Amgen and Algeta (OSE: ALGETA), an oncology company developing treatments for bone metastases and disseminated tumours.
For more information, please contact:
Advent Life Sciences
Ph: +44 (0) 20 7932 2100